Latest Funding News

Rimfire Pacific Mining is advancing its position as a leading scandium explorer in Australia’s Fifield district, with plans for new Mineral Resource Estimates and a $3.5 million capital raise to fund drilling and exploration. Joint ventures with Golden Plains Resources have been reinstated, underpinning a strategic push in a critical mineral market facing supply constraints.

Rimfire Pacific Mining Limited has had its trading suspension lifted immediately following the release of its capital raising results, signaling renewed market activity.

Rimfire Pacific Mining has secured $3.5 million through a discounted share placement to accelerate scandium resource development across its NSW projects, signaling renewed momentum after arbitration setbacks.

Fat Prophets Global Contrarian Fund Ltd announces a special fully franked dividend of AUD 0.05 per share, coupled with a dividend reinvestment plan offering a 2.5% discount. Key dates for investors are set for late August and September 2025.

Fat Prophets Global Contrarian Fund has announced a fully franked special dividend of 5 cents per share, reflecting strong investment performance. The dividend reinvestment plan offers shareholders a 2.5% discount on reinvested shares, signaling confidence in future growth.

Lachlan Star Limited reports promising maiden drilling results at its Killaloe Gold Project in Western Australia and initiates copper-gold drilling at North Cobar, NSW, while securing permits for further Basin Creek exploration.

Astute Metals NL sharpens its focus on Nevada’s rich mineral landscape, unveiling fresh high-grade gold targets at Needles and reaffirming lithium potential at Red Mountain amid leadership changes.

Amplia Therapeutics has launched a $27.5 million capital raising to advance its lead drug Narmafotinib, a promising FAK inhibitor showing superior efficacy in pancreatic cancer trials. The funds will support ongoing and new clinical studies, positioning the company for pivotal regulatory milestones.

Amplia Therapeutics has successfully raised A$25 million through an institutional placement and launched a A$2.5 million Share Purchase Plan to fund pivotal clinical trials of its lead drug narmafotinib. The capital injection positions the company to advance key pancreatic and ovarian cancer studies into 2027.

IperionX has successfully commissioned its Virginia titanium manufacturing campus, secured a substantial U.S. Department of Defense contract, and raised $46 million to fast-track production expansion through 2030.

Lake Resources has raised $2.1 million through its At-the-Market facility by issuing 65 million shares to Acuity Capital, while extending the agreement to 2031 to support its Kachi Project and working capital needs.

Bowen Coking Coal’s initial attempt to defer state royalty payments has been declined by the Queensland Revenue Office, prompting plans for a revised proposal amid ongoing debt restructuring efforts.